NEW YORK (GenomeWeb) – Agendia said today that it has signed a marketing agreement with Angsana Molecular & Diagnostics Laboratory for Agendia's MammaPrint and BluePrint breast cancer tests in Southeast Asia.
MammaPrint analyzes 70 genes associated with breast cancer recurrence to provide a binary low or high risk of cancer recurrence to help physicians decide which individuals can forgo chemotherapy. BluePrint includes 80 genes and classifies a patient's breast cancer into one of four functional molecular subtypes.
Under the terms of the deal, diagnostic developer Angsana will market the tests to physicians in Singapore, Malaysia, Vietnam, Brunei, and Myanmar. Â
Additional terms were not disclosed.
"Southeast Asia represents a significant growth opportunity for Agendia and a commercial priority for the company," Agendia Chief Commercial Officer Chris Barbazette said in a statement. "With their extensive experience in molecular diagnostics and regional insight, Angsana is an ideal partner as we continue to build our presence in this rapidly evolving market."
In addition to its own diagnostics, Singapore-based Angsana offers tests from Admera Health and Counsyl in Asia.